DDX18 Inhibitors
DDX18 inhibitors are a class of chemical compounds that specifically target and inhibit the DDX18 protein, a member of the DEAD-box family of RNA helicases. DDX18 is involved in various processes of RNA metabolism, including the unwinding of RNA structures, ribosome biogenesis, and RNA processing. As an ATP-dependent RNA helicase, DDX18 utilizes the energy from ATP hydrolysis to unwind complex RNA structures, which is essential for the maturation of ribosomal RNA (rRNA) and for ensuring proper ribosome assembly. By inhibiting DDX18, these compounds disrupt the RNA helicase's ability to perform these critical functions, leading to alterations in RNA metabolism and ribosome formation within the cell.
The structural design of DDX18 inhibitors is focused on interfering with the enzyme's ATP-binding site or its RNA-binding domain. Competitive inhibitors typically block the active site where ATP binds, preventing the hydrolysis that powers RNA unwinding. Alternatively, inhibitors may bind to allosteric sites on the DDX18 protein, causing conformational changes that reduce its helicase activity. The inhibition of DDX18 provides valuable insights into its role in cellular RNA dynamics, particularly in the context of ribosome production and RNA structural remodeling. Research into DDX18 inhibitors helps uncover the detailed mechanisms by which DDX18 governs RNA-protein interactions and how it contributes to the regulation of gene expression and overall RNA homeostasis. The study of these inhibitors is crucial for expanding our understanding of RNA helicase function and the broader aspects of RNA biology within cells.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin (Sirolimus) binds to the FKBP12 protein forming a complex that inhibits the mTOR pathway, leading to a decrease in protein synthesis, which includes the downregulation of DDX18 expression. | ||||||
Triptolide | 38748-32-2 | sc-200122 sc-200122A | 1 mg 5 mg | $90.00 $204.00 | 13 | |
Triptolide covalently modifies the XPB subunit of the transcription factor TFIIH, leading to the inhibition of RNA polymerase II-mediated transcription and subsequent reduction in DDX18 mRNA levels. | ||||||
Doxorubicin | 23214-92-8 | sc-280681 sc-280681A | 1 mg 5 mg | $176.00 $426.00 | 43 | |
Doxorubicin intercalates within DNA, disrupting the DNA replication and transcription processes, and inhibits topoisomerase II, which collectively result in reduced expression of genes such as DDX18. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $69.00 | 2 | |
Chloroquine concentrates in the lysosomes, raising their pH and hindering their function, which can lead to the suppression of autophagy-related degradation of transcriptional regulators, subsequently reducing DDX18 expression. | ||||||
Mithramycin A | 18378-89-7 | sc-200909 | 1 mg | $55.00 | 6 | |
Mithramycin A selectively binds to GC-rich sequences in DNA, displacing transcription factors and specifically inhibiting the transcription of certain genes, potentially including the gene encoding DDX18. | ||||||
Mitomycin C | 50-07-7 | sc-3514A sc-3514 sc-3514B | 2 mg 5 mg 10 mg | $66.00 $101.00 $143.00 | 85 | |
Mitomycin C alkylates DNA, forming crosslinks and leading to the cessation of DNA synthesis and transcription, which can downregulate the expression of genes such as DDX18. | ||||||
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $231.00 $863.00 | 1 | |
JQ1 disrupts the interaction between BET bromodomain proteins and acetylated histones, leading to the repression of BRD4-regulated genes, potentially decreasing the transcription levels of DDX18. | ||||||
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $259.00 | 41 | |
Flavopiridol competitively inhibits several cyclin-dependent kinases (CDKs), which can halt RNA polymerase II progression, leading to the reduction in elongation and processing of DDX18 mRNA transcripts. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib inhibits the 26S proteasome, which prevents the degradation of ubiquitinated proteins, causing an accumulation of misfolded proteins and a general downregulation of protein synthesis, including that of DDX18. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
EGCG has been shown to inhibit DNA methyltransferases, which could lead to hypomethylation and subsequent silencing of certain genes. It might also hinder the expression of DDX18 through alterations in DNA methylation patterns. | ||||||